Revolution Medicines, Inc.
RVMDDrugs in Pipeline
5
Phase 3 Programs
2
Upcoming Catalysts
2
Next Catalyst
Q2 2027
Market Overview
Stock performance and key metrics
3 upcoming, 0 past
How RVMD's past catalysts played out
daraxonrasib
NSCLC (Non-small Cell Lung Cancer)
RMC-6236
Colorectal Cancer
RMC-4630
Non-Small Cell Lung Cancer
RMC-6291
Non-Small Cell Lung Cancer, NSCLC
Cobimetinib
Solid Tumor
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
daraxonrasib | Phase 3 | NSCLC (Non-small Cell Lung Cancer) | - | - |
RMC-6236 | Phase 3 | Colorectal Cancer | - | - |
RMC-4630 | Phase 2 | Non-Small Cell Lung Cancer | - | - |
RMC-6291 | Phase 2 | Non-Small Cell Lung Cancer, NSCLC | - | - |
Cobimetinib | Phase 2 | Solid Tumor | - | - |
Colorectal Cancer
1 drug in this indication
Non-Small Cell Lung Cancer, NSCLC
1 drug in this indication
Solid Tumor
1 drug in this indication
NSCLC (Non-small Cell Lung Cancer)
1 drug in this indication
Non-Small Cell Lung Cancer
1 drug in this indication
non-small cell lung cancer (RAS mutant)
1 drug in this indication
metastatic pancreatic cancer
1 drug in this indication
pancreatic cancer
1 drug in this indication
pancreatic ductal adenocarcinoma
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Revolution Medicines, Inc.'s drug pipeline?→
CatalystAlert tracks 5 drug candidates in Revolution Medicines, Inc.'s (RVMD) pipeline across Phase 3, Phase 2. Its lead program is daraxonrasib (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Revolution Medicines, Inc.'s next FDA catalyst?→
Revolution Medicines, Inc.'s (RVMD) next tracked catalyst is a Phase 2 expected May 15, 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track RVMD biotech catalysts?→
Add RVMD to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Revolution Medicines, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.